Sean Harper, Stefan Scherer

Search­ing for new TCR tar­gets, im­munother­a­py start­up emerges with Stan­ford tech, $40M round

In the last decade, im­munother­a­py, which in­volves the us­age of a pa­tient’s own im­mune cells to fight can­cers, has gained great mo­men­tum. In one vari­a­tion, the treat­ment in­volves re­mov­ing a pa­tient’s T cells, a type of white blood cell, and en­abling them to rec­og­nize pro­teins that are on­ly present in can­cer cells. Up­on find­ing its neme­sis the T cells at­tack the can­cer cells. But the ma­jor chal­lenge re­searchers face is dis­cov­er­ing more and more of these pro­teins that are dis­played specif­i­cal­ly on can­cer cells, said Ste­fan Scher­er, CEO of 3T Bio­sciences, a San Fran­cis­co-based biotech.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.